Accenture May 25, 2021
RESEARCH REPORT
In brief
- A new economic environment is demanding change for biopharma’s, especially as New Science grows in prominence.
- New Science, the combo of advanced science and tech, is expected to drive 81 percent biopharma revenue growth, but is more expensive to develop.
- What if biopharma companies could tie profitability to innovation, growth, and better patient outcomes made possible by New Science?
- It’s time to rebalance the treatment-cost equation from old ways of operating to new ways of discovering, developing and commercializing treatments.
How do you lead amidst change?
Today's Sponsors
Today's Sponsor